Skip to main content
ANAGENICS LIMITED logo

ANAGENICS LIMITED — Investor Relations & Filings

Ticker · AN1 ISIN · AU0000198095 ASX Manufacturing
Open in API
Filings indexed 1,067 across all filing types
Latest filing 2020-08-26 Annual Report
Country AU Australia
Listing ASX AN1

About ANAGENICS LIMITED

https://anagenics.com

Anagenics Limited is a health and wellness company focused on the development and commercialization of science-based anti-aging and longevity solutions. The company specializes in the research and distribution of clinically validated products targeting hair loss and skin health. Its core portfolio includes the évolis brand, which utilizes proprietary FGF5 inhibitor technology to promote hair growth and improve hair health. Through its subsidiaries, such as Advangen and BLC Cosmetics, the company manages a diverse range of premium skincare and wellness brands. Anagenics operates across international markets, providing consumer-facing products and professional-grade treatments backed by scientific research. The company's strategic focus remains on expanding its presence in the global beauty-tech and wellness sectors by leveraging its intellectual property and distribution networks.

Recent filings

Filing Released Lang Actions
FY20 Results Presentation 21 pages 1.9MB
Annual Report Classification · 90% confidence The document is titled 'FY2020 Financial Results' and dated 27 August 2020. It contains detailed financial data including revenue, profit/loss, balance sheet items, segment reporting by geography, and operational highlights for the fiscal year 2020. The content includes comprehensive financial performance analysis, business segment results, growth strategy, and outlook. The length is substantial (15,000 characters), and the document is a detailed presentation of the full fiscal year financial results rather than a brief announcement or a certification. This matches the characteristics of an Interim / Quarterly Report (IR) or Annual Report (10-K). Since it covers a full fiscal year (FY2020) and includes detailed financial statements and analysis, it aligns best with an Annual Report (10-K) type document. However, the document is presented as a financial results presentation, which is often classified as an Investor Presentation (IP). But given the depth of financial data and segment reporting, it is more than a presentation and resembles a full financial report. The document is not a short announcement or a report publication notice, nor is it a call transcript or management change notice. Therefore, the best fit is Annual Report (10-K). FY 2020
2020-08-26 English
CDY Signs Agreement With Premium Salon Distributor in USA 2 pages 72.4KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement detailing a new exclusive distribution agreement between Cellmid and Tru Beauty Concepts Inc. in the USA. It focuses on business expansion, distribution channels, and expected revenue impact. There are no financial statements, quarterly or annual results, or detailed financial data presented. The content is about a business development and partnership agreement rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is a corporate announcement about a commercial agreement, which aligns best with Capital/Financing Update (CAP) as it relates to business growth and revenue prospects through a new distribution deal. The document length is 4889 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the most appropriate classification is CAP with high confidence.
2020-07-27 English
Appendix 4C and Quarterly Activity Report 10 pages 319.0KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement titled 'CELLMID APPENDIX 4C – Q4 FY2020 BUSINESS ACTIVITY' and includes detailed quarterly business activity and financial highlights for the quarter ending 30 June 2020. It contains unaudited revenue figures, sales performance, updates on trading and distribution agreements, and cash flow information. The presence of the Appendix 4C quarterly cash flow report, which is a regulatory requirement for Australian listed entities, confirms this is a quarterly report. The document is comprehensive and contains substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. It is not merely an announcement of a report or a certification, and it is not a full annual report or earnings release. Therefore, the correct classification is Interim / Quarterly Report (IR). Q4 2020
2020-07-21 English
Cellmid Signs Exclusive Agreement For Sars-Cov-2 Laboratory 3 pages 99.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 9 July 2020 from Cellmid Limited regarding the signing of an exclusive distribution agreement for SARS-CoV-2 laboratory tests. It details the terms of the agreement, the products involved, their evaluation data, and regulatory considerations. The content focuses on a business update about a new agreement and product distribution, not on financial results, management changes, or regulatory filings. The document length is 7220 characters, which is sufficient for a detailed announcement but does not contain financial statements or detailed financial analysis. There is no indication that this is a full financial report, audit report, or earnings release. It is clearly an announcement about a capital or business development activity related to product distribution and agreements. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-07-08 English
Response to ASX Aware Query 5 pages 225.0KB
Regulatory Filings Classification · 95% confidence The document is a letter from the company Cellmid Limited responding to an ASX (Australian Securities Exchange) Aware query regarding a previous announcement about an amendment to a supply agreement. The letter addresses compliance with continuous disclosure obligations under ASX Listing Rules 3.1 and 3.1A, explaining why the information was not considered material and confirming compliance. The content is a regulatory correspondence related to disclosure and compliance rather than a financial report, earnings release, or other specific report type. It is not a report itself but a regulatory filing responding to a query from the exchange. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (9854 characters) and detailed regulatory discussion support this classification rather than a brief announcement or report publication notice.
2020-07-08 English
Pause in Trading 1 page 108.8KB
Regulatory Filings Classification · 95% confidence The document is a brief market release announcing a temporary pause in trading of the company's securities. It is very short (330 characters) and does not contain financial data, report content, or detailed information. It is an official regulatory announcement related to trading status, not a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-07-06 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.